Sign In  |  Register  |  About Los Altos  |  Contact Us

Los Altos, CA
September 01, 2020 1:26pm
7-Day Forecast | Traffic

  • Search Hotels in Los Altos

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amgen (NQ: AMGN )

289.90 +2.03 (+0.71%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amgen

< Previous 1 2 3 4 5 6 7 8 9
...
47 48 Next >
Eli Lilly Stock Tumbles As Kennedy Targets Weight Loss Drugs
LLY stock struggles, falling 16.85% over the last month due to bearish technicals and political uncertainty. But with projected sales and earnings growth, could this be a buying opportunity? 
Via Benzinga
Decoding Amgen's Options Activity: What's the Big Picture?
Via Benzinga
Silence Therapeutics' Zerlasiran Has Competitive Concerns: Analyst
Silence Therapeutics' Phase 2 data shows zerlasiran achieves over 80% Lp(a) reduction in ASCVD patients but faces dosing frequency challenges. 
Via Benzinga
Neurogene, Nvidia And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
Dow Tumbles Over 300 Points Following Economic Reports, Nvidia, Microsoft Decline: Fear & Greed Index Moves To 'Neutral' Zone
Via Benzinga
Topics Stocks
Exposures US Equities
Amgen's Options Frenzy: What You Need to Know
Via Benzinga
What Analysts Are Saying About Amgen Stock
Via Benzinga
3 Healthcare Stocks For Long-Term Growth And Dividends
Healthcare stocks will profit from the U.S. aging population and pay rising dividends over time. 
Via Talk Markets
2 Reasons to Buy Amgen Stock, and 1 Reason to Be Cautious
Its future is bright, but that doesn't mean it'll always be smooth sailing. 
Via The Motley Fool
AMGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Amgen Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Want Decades of Passive Income? Buy This Index Fund and Hold It Forever
This fund could be the perfect investment for those wanting financial freedom through endlessly growing dividends. 
Via The Motley Fool
2 Dividend Stocks to Buy Hand Over Fist in November
These companies have solid businesses and excellent dividend growth track records. 
Via The Motley Fool
Amgen Defends Its Investigational Monthly Weight Loss Injection After Analyst Cites MariTide's Impact on Bone Density
Amgen addresses safety concerns for its weight loss drug MariTide after new data suggests a potential 4% reduction in bone density at the highest dose. 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Amgen Rebounds, Shaking Off 'Overdone' Fears Tied To Its Weight-Loss Shot
Shares were rattled Tuesday after a report showed its obesity treatment can cause lower bone mineral density. 
Via Investor's Business Daily
Jim Cramer Says Eli Lilly's 'Pathetic' Stock Performance Could Get A Breather If Amgen Has Hidden Bone Risk Data After 7% Stock Drop
Amgen Inc.'s stock dropped over 7% on Tuesday following revelations about bone density loss in early trials of its experimental obesity drug MariTide, while CNBC's Jim Cramer suggested the news could... 
Via Benzinga
Amgen Drops 7% After A 'Big Unknown Risk' Rattles Its Monthly Obesity Shot
The company is testing MariTide as a monthly shot, rivaling weekly injections from Novo Nordisk and Eli Lilly. 
Via Investor's Business Daily
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Don’t Confuse Brains With A Bull Market, Or Price With Value
If you are interested in the stock market, maybe it is time to stop focusing on The Fed. 
Via Talk Markets
Investors Like Certainty. Trump's Win Gave Them Some.
We're also talking about Super Micro, Nvidia, and weight loss. 
Via The Motley Fool
Topics Government
Exposures Political
AstraZeneca/Amgen's Asthma Drug Aces Late-Stage Study In Patients With Chronic Rhinosinusitis
AstraZeneca and Amgen's Phase 3 trial data shows Tezspire significantly reduces nasal polyps and congestion in patients with chronic rhinosinusitis with nasal polyps. 
Via Benzinga
Upstream Bio Is New On NASDAQ, Can Potentially Beat AstraZeneca's Asthma Drug On Efficacy, Analysts Say
Upstream Bio garners analyst optimism for its lead drug verekitug, which could disrupt the $7.5 billion asthma biologics market. 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Amgen (AMGN) Q3 2024 Earnings Call Transcript
AMGN earnings call for the period ending September 30, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Amgen 'Laser-Focused' On Its Weight-Loss Shot As New Rival Pfizer Follows, Says CFO
The company expects to have topline results from a Phase 2 study later this year. 
Via Investor's Business Daily
Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights
Novartis aims to enhance Pluvicto's market presence while exploring growth in multiple sclerosis and expanding its radioligand therapy portfolio. 
Via Benzinga
Stock Market Retreats Before Election Day; Microsoft, Apple, Amazon, Google, Meta In Focus: Weekly Review
The major indexes declined, but haven't fallen apart. 
Via Investor's Business Daily
Wall Street Mixed, Semiconductors Tumble As AMD Disappoints, Alphabet Rallies, SMCI Plummets: What's Driving Markets Wednesday?
Wall Street experienced a mixed trading session on Wednesday as investors weigh a batch of corporate earnings and fresh economic data. 
Via Benzinga
Stocks Tumble, Nasdaq 100 Selloffs As Tech Giants Disappoint, Crypto Companies Plummet: What's Driving Markets Thursday?
Risk aversion swept across markets on Thursday as investor disappointment over third-quarter tech earnings triggered the steepest drop in major U.S. indices in nearly two months. 
Via Benzinga
Stock-Split Watch: 2 Healthcare Stocks That Look Ready to Split
One of these players has split its stock in the past. The other one hasn't. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
47 48 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 LosAltos.com & California Media Partners, LLC. All rights reserved.